RESUMEN
The mechanisms controlling degradation of cytosolic ß-catenin are important for regulating ß-catenin co-transcriptional activity. Loss of von Hippel-Lindau protein (pVHL) has been shown to stabilize ß-catenin, increasing ß-catenin transactivation and ß-catenin-mediated cell proliferation. However, the role of phosphoinositide 3-kinase (PI3K)/Akt in the regulation of ß-catenin signaling downstream from pVHL has never been addressed. Here, we report that hyperactivation of PI3K/Akt in cells lacking pVHL contributes to the stabilization and nuclear accumulation of active ß-catenin. PI3K/Akt hyperactivation is facilitated by the up-regulation of 14-3-3ζ and the down-regulation of 14-3-3ε, 14-3-3η and 14-3-3θ. Up-regulation of 14-3-3ζ in response to pVHL is important for the recruitment of PI3K to the cell membrane and for stabilization of soluble ß-catenin. In contrast, 14-3-3ε and 14-3-3η enhanced PI3K/Akt signaling by inhibiting PI3K and PDK1, respectively. Thus, our results demonstrated that 14-3-3 family members enhance PI3K/Akt/ß-catenin signaling in order to increase proliferation. Inhibition of Akt activation and/or 14-3-3 function strongly reduces ß-catenin signaling and decreases cell proliferation. Thus, inhibition of Akt and 14-3-3 function efficiently reduces cell proliferation in 786-0 cells characterized by hyperactivation of ß-catenin signaling due to pVHL loss.
Asunto(s)
Proteínas 14-3-3/biosíntesis , Proliferación Celular/fisiología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/fisiología , Regulación hacia Arriba/fisiología , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/metabolismo , beta Catenina/metabolismo , Proteínas 14-3-3/genética , Animales , Perros , Humanos , Células de Riñón Canino Madin Darby , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/genética , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/genética , beta Catenina/genéticaRESUMEN
Gene therapy is a new modality of treatment in which a gene is used to modify or add new biochemical properties to a patient's target cells with therapeutics purposes. Currently, this experimental therapy is under intensive development as an alternative to treat cancer, because it is possible that this therapy may generate a higher antineoplastic activity, more tissue selectivity and less contralateral effects than conventional therapy. After a decade of preclinical and clinical assays, still there are several obstacles that impose limits to the antineoplastic efficacy of this therapy. However, with the advances in molecular biology and related fields, there is a promise to improve, expand and strength the powerful antineoplastic arsenal of gene therapy.
Asunto(s)
Terapia Genética , Neoplasias/terapia , Ensayos Clínicos como Asunto , Vectores Genéticos , Humanos , Inmunoterapia , Neoplasias/genética , Transducción GenéticaRESUMEN
Gene therapy is a new modality of treatment in which a gene is used to modify or add new biochemical properties to a patient's target cells with therapeutics purposes. Currently, this experimental therapy is under intensive development as an alternative to treat cancer, because it is possible that this therapy may generate a higher antineoplastic activity, more tissue selectivity and less contralateral effects than conventional therapy. After a decade of preclinical and clinical assays, still there are several obstacles that impose limits to the antineoplastic efficacy of this therapy. However, with the advances in molecular biology and related fields, there is a promise to improve, expand and strength the powerful antineoplastic arsenal of gene therapy.